Needham & Company LLC Reiterates “Buy” Rating for Solid Biosciences (NASDAQ:SLDB)

Solid Biosciences (NASDAQ:SLDB)‘s stock had its “buy” rating reissued by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $19.00 price target on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 170.27% from the company’s current price.

Several other brokerages have also issued reports on SLDB. Citigroup restated a “market outperform” rating on shares of Solid Biosciences in a research note on Wednesday, December 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Solid Biosciences in a research note on Thursday, January 22nd. Chardan Capital reissued a “buy” rating and issued a $15.00 price objective on shares of Solid Biosciences in a report on Thursday, March 12th. Finally, Wedbush restated an “outperform” rating and issued a $14.00 price objective on shares of Solid Biosciences in a research note on Wednesday, March 11th. Eleven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $16.00.

Solid Biosciences Stock Down 1.3%

Shares of SLDB stock opened at $7.03 on Friday. The firm has a market cap of $547.71 million, a P/E ratio of -3.48 and a beta of 2.65. The company has a 50 day moving average of $6.43 and a 200-day moving average of $5.80. Solid Biosciences has a 12-month low of $2.41 and a 12-month high of $8.72.

Solid Biosciences (NASDAQ:SLDB) last posted its quarterly earnings data on Thursday, March 19th. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.01. As a group, equities analysts expect that Solid Biosciences will post -2.84 EPS for the current year.

Insider Transactions at Solid Biosciences

In other news, CFO Kevin Tan sold 5,404 shares of the firm’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $5.82, for a total value of $31,451.28. Following the completion of the transaction, the chief financial officer directly owned 99,422 shares in the company, valued at approximately $578,636.04. This trade represents a 5.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ilan Ganot sold 7,205 shares of the business’s stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $6.44, for a total transaction of $46,400.20. Following the transaction, the director directly owned 25,271 shares of the company’s stock, valued at approximately $162,745.24. This represents a 22.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 597,672 shares of company stock valued at $3,816,546. Company insiders own 1.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in SLDB. Legal & General Group Plc raised its position in shares of Solid Biosciences by 208.6% in the second quarter. Legal & General Group Plc now owns 6,011 shares of the company’s stock worth $29,000 after buying an additional 4,063 shares in the last quarter. Ameritas Investment Partners Inc. raised its holdings in shares of Solid Biosciences by 205.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,740 shares of the company’s stock valued at $33,000 after acquiring an additional 4,534 shares in the last quarter. Creative Planning bought a new stake in shares of Solid Biosciences during the 2nd quarter valued at about $57,000. Russell Investments Group Ltd. boosted its position in shares of Solid Biosciences by 142.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 10,211 shares of the company’s stock valued at $63,000 after acquiring an additional 5,991 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey grew its holdings in shares of Solid Biosciences by 233.8% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 15,113 shares of the company’s stock worth $74,000 after purchasing an additional 10,585 shares in the last quarter. Institutional investors own 81.46% of the company’s stock.

Solid Biosciences News Summary

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: Guggenheim started coverage with a Buy and a $26 price target (implies ~272% upside from recent levels), giving formal street-level momentum and a large upside case for the stock. Guggenheim starts coverage (Benzinga)
• Positive Sentiment: Needham reaffirmed Buy with a $19 price target, signaling continued analyst conviction in the company’s clinical progress and longer-term value. Needham reaffirms buy (Benzinga)
• Positive Sentiment: Chardan reaffirmed its Buy rating and $15 target, adding to the cluster of upgrade/reaffirmation headlines that can attract investor attention and trading demand. Chardan reaffirms buy (TickerReport)
• Positive Sentiment: Solid reported positive interim Phase 1/2 INSPIRE data for SGT-003 at the 2026 MDA meeting; the readout highlights generally favorable tolerability in 41 dosed participants—this is the primary fundamental catalyst supporting higher valuations. SGT-003 interim data (GlobeNewswire)
• Neutral Sentiment: The company issued its Q4 and full-year 2025 results and broader business updates; the release contains operational context and program timelines that investors will parse for runway and development plans. Q4 & full-year 2025 results (FinanzNachrichten)
• Negative Sentiment: SLDB missed Q4 EPS expectations (reported -$0.53 vs. consensus -$0.48), underlining ongoing losses and near-term profitability risk that likely capped the stock’s upside today. Earnings press release (Quartr)

Solid Biosciences Company Profile

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.